Treatment page
ABOUT PHOTODYNAMIC THERAPY
PDT or Photodynamic therapy: A form of cancer treatment using an photosensitizing agent administered intravenously which concentrates selectively in tumor cells, followed by exposure of the tumor tissue to a special red laser light, in order to destroy as much of the tumor as possible.
Photodynamic therapy is also called, descriptively, photochemotherapy.
Source.
MedicineNet.(com)
"If I had the choice, would I rather have surgery to cut out part or all of my tongue, or have a treatment that left me still with my ability to eat and talk normally?"
"If I could have a skin cancer treatment that didn’t leave a hollow or a scar – or worse still require me to have a ‘patch’ of skin transplanted to fill the hole where the cancer had been cut out – which option would be my choice?""If I could have a lung cancer treatment that didn’t remove my lung, would I prefer that choice?"
"If I could have a cancer treatment that could be a one-off – not months of chemotherapy, radiotherapy or major surgery –
I think you know what I would say."
Source.
Killing Cancer
Photodynamic therapy: a promising new modality for the treatment of cancer.Schuitmaker JJ, Baas P, van Leengoed HL, van der Meulen FW, Star WM, van Zandwijk N.SourceDepartment of Ophthalmology, Academic Hospital of the University of Leiden, Sylvius Laboratory, Netherlands.
AbstractThe first reports on photodynamic therapy (PDT) date back to the 1970s. Since then, several thousands of patients, both with early stage and advanced stage solid tumours, have been treated with PDT and many claims have been made regarding its efficacy. Nevertheless, the therapy has not yet found general acceptance by oncologists. Therefore it seems legitimate to ask whether PDT can still be described as "a promising new therapy in the treatment of cancer". Clinically, PDT has been mainly used for bladder cancer, lung cancer and in malignant diseases of the skin and upper aerodigestive tract. The sensitizer used in the photodynamic treatment of most patients is Photofrin, (Photofrin, the commercial name of dihematoporphyrin ether/ester, containing > 80% of the active porphyrin dimers/oligomers (A.M.R. Fisher, A.L. Murphee and C.J. Gomer, Clinical and preclinical photodynamictherapy, Review Series Article, Lasers Surg. Med., 17 (1995) 2-31). It is a complex mixture of porphyrins derived from hematoporphyrin. Although this sensitizer is effective, it is not the most suitable photosensitizer for PDT. Prolonged skin photosensitivity and the relatively low absorbance at 630 nm, a wavelength where tissue penetration of light is not optimal, have been frequently cited as negative aspects hindering general acceptance. A multitude of new sensitizers is currently under evaluation. Most of these "second generation photosensitizers" are chemically pure, absorb light at around 650 nm or greater and induce no or less general skin photosensitivity. Another novel approach is the photosensitization of neoplasms by the induction of endogenous photosensitizers through the application of 5-aminolevulinic acid (ALA). This article addresses the use of PDT in the disciplines mentioned above and attempts to indicate developments of PDT which could be necessary for this therapy to gain a wider acceptance in the various fields.
Source.
Department of Ophthalmology, Academic Hospital of the University of Leiden, Sylvius Laboratory, Netherlands.
PMID
High and sustained efficacy after two sessions of topical 5-aminolaevulinic acid photodynamic therapy for basal cell carcinoma: a prospective, clinical and histological 10-year follow-up study.
Christensen E, Mørk C, Skogvoll E.
Abstract
Background: Prolonged follow-up data on topical photodynamic therapy (PDT) in basal cell carcinoma (BCC) is necessary for a full evaluation of its effect and for comparison with conventional treatments methods. Objective: To assess 10-year long-term PDT efficacy in primary and recurrent BCC and to evaluate clinical and histopathological factors which may be associated with treatment failure. Methods: We performed a longitudinal study on 60 histologically verified BCCs in 44 patients treated with curettage and one or two sessions with dimetylsulfoxide (DMSO)-supported topical 5-aminolaevulinic acid (ALA) - PDT. Treated lesions were investigated by clinical and histopathological examination at regular intervals. The main outcomes were 10-year lesion complete response rate using a time to event analysis, histological treatment failure and cosmesis. Results: Overall complete response rate for all lesions was 75% (95% confidence interval 64%-87%); 60% after one and 87% after two treatment sessions. The response rate was 78% for primary lesions; 63% after one and 90% after two sessions. The cosmetic outcome was rated as good or excellent in 91 to 100% of evaluated cases. Treatment failure was documented in 15 (25%) of 60 lesions; clinical investigation identified 14 of them. All failures were noted within 3 years of treatment. Male gender, recurrent tumour and one treatment session were factors significantly associated with treatment failure. The only lesion larger than 2.0 cm. relapsed. Conclusion: Two sessions of DMSO supportive topical ALA-PDT and curettage can provide long-term effective treatment results with favourable cosmetic outcome in primary, small BCC.
Copyright © 2012 British Association of Dermatologists.
sOURCE.
Department of Dermatology, St. Olav's University Hospital HF, Institute of Cancer Research and Molecular Medicine, Faculty of Medicine, Norwegian University of Science and Technology (NTNU), Trondheim, Norway. Dermatology Unit, Institute of Cancer Research and Molecular Medicine, Faculty of Medicine, Norwegian University of Science and Technology (NTNU), Trondheim, Norway. Department of Anaesthesiology and Emergency Medicine, St.Olav's University Hospital HF, Unit for Applied Clinical Research, Institute ofCancer Research and Molecular Medicine, Faculty of Medicine,Norwegian University of Science and Technology (NTNU), Trondheim, Norway.
Help us to get Henry PDT Therapy!!!!!!
Henry will die in four months if he does not get chemotherapy treatment urgently.
Henry will also die in 12 to 18 months if he does get chemotherapy treatment.
Henry could live many more years if we help him to get PDT Treatment.
Henry will also die in 12 to 18 months if he does get chemotherapy treatment.
Henry could live many more years if we help him to get PDT Treatment.
Runner up in the national Killing Cancer animation competition, judged by BBC Arts staff, Matthew Wright from Channel 4 and a music video director. Music by Hawkwind legend Huw Lloyd-Langton.
|